Is JAK3 a new drug target for immunomodulation-based therapies?

Trends in Pharmacological Sciences

Volumn 25, Issue 11, 2004, Pages 558-562

  Papageorgiou, Anastassios C ^a   Wikman, Linnea E K ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2 NAPHTHYLVINYLKETONE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; CP 352664; CYCLOSPORIN; CYTOKINE RECEPTOR; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE; JANUS KINASE 3; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHOTRANSFERASE INHIBITOR; PNU 156804; PROTEIN TYROSINE KINASE; ROSMARINIC ACID; STAUROSPORINE; STREPTOZOCIN; UNCLASSIFIED DRUG; WHIP 154; WHIP 97;

ALLERGY; AMYOTROPHIC LATERAL SCLEROSIS; ANEMIA; ASTHMA; AUTOIMMUNITY; CATALYSIS; CELL MATURATION; CELLULAR IMMUNITY; DIABETES MELLITUS; DRUG TARGETING; GRAFT REJECTION; HEMATOPOIETIC SYSTEM TUMOR; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TH2 CELL; THROMBOEMBOLISM; TRANSPLANTATION;

EID: 5644242144     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.09.008     Document Type: Article

References (48)

1. C. Schindler Cytokines and JAK-STAT signaling Exp. Cell Res. 253 1999 7 14
2. J.J. O'Shea Cytokine signaling in 2002: new surprises in the JAK/STAT pathway Cell 109 2002 S121 S131
3. C. Schindler JAK-STAT signaling in human disease J. Clin. Invest. 109 2002 1133 1137
4. P. Lamb Biochemical approaches to discovering modulators of the JAK-STAT pathway Drug Discov. Today 3 1998 122 130
5. J. Turkson, and R. Jove STAT proteins: novel molecular targets for cancer drug discovery Oncogene 19 2000 6613 6626
6. K. Inagaki-Ohara Negative regulation of cytokine signaling and inflammatory diseases Curr. Opin. Pharmacol. 3 2003 435 442
7. M. Cetkovic-Cvrlje, and H.E. Tibbles Therapeutical potential of Janus kinase 3 (JAK3) inhibitors Curr. Pharm. Des. 10 2004 1767 1784
8. A. Halupa, and D.L. Barber Specificity in JAK-STAT signaling J. Woodgett Protein Kinase Functions p.cm Frontiers in Molecular Biology Functions 2000 Oxford University Press 194 245
9. S.M. Russell Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development Science 270 1995 797 800
10. J.J. O'Shea JAK3 and the pathogenesis of severe combined immunodeficiency Mol. Immunol. 41 2004 727 737
11. M. Noguchi Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans Cell 73 1993 147 157
12. K. Tomita Cytokine-independent JAK3 activation upon T cell receptor (TCR) stimulation through direct association of JAK3 and the TCR complex J. Biol. Chem. 276 2001 25378 25385
13. F. Cagnoni CD40 on adult human airway epithelial cells: expression and proinflammatory effects J. Immunol. 172 2004 3205 3214
14. T.C. Yeh, and S. Pellegrini The Janus kinase family of protein tyrosine kinases and their role in signaling Cell. Mol. Life Sci. 55 1999 1523 1534
15. N. Meydan Inhibition of acute lymphoblastic leukaemia by Jak-2 inhibitor Nature 379 1996 645 648
16. K. Kumano Blockade of JAK2 by tyrphostin AG-490 inhibits antigen-induced eosinophil recruitment into the mouse airways Biochem. Biophys. Res. Commun. 270 2000 209 214
17. L. Wang JAK3, STAT and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2 mediated T cell response J. Immunol. 162 1999 3897 3904
18. G.R. Brown Napthyl ketones: a new class of Janus kinase 3 inhibitors Bioorg. Med. Chem. Lett. 10 2000 575 579
19. E.A. Sudbeck Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents Clin. Cancer Res. 5 1999 1569 1582
20. R. Malaviya Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′,5′- dibromo-4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97) J. Pharmacol. Exp. Ther. 295 2000 912 926
21. M. Cetkovic-Cvrlje Targeting JAK3 with JANEX-1 for prevention of autoimmune type I diabetes in NOD mice Clin. Immunol. 106 2003 213 225
22. A. Mortellaro New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-κB and AP-1 activation J. Immunol. 162 1999 7102 7109
23. S.M. Stepowski Selective inhibitor of Janus kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin Blood 99 2002 680 689
24. S. Yun The role of IL-2 in allograft rejection-A lesson learned from experimental work Transplantation 69 2000 2480 2483
25. D.A. Jacobsohn, and G.B. Vogelsang Anti-cytokine therapy for the treatment of graft-versus-host disease Curr. Pharm. Des. 10 2004 1195 1205
26. P.S. Changelian Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor Science 302 2003 875 878
27. M. Sykes JAKing up immunosuppression Nat. Med. 9 2003 1458 1459
28. Z. Dai, and F.G. Lakkis The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection Curr. Opin. Immunol. 11 1999 504 508
29. P. Cohen Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1 2002 309 315
30. M.E.M. Noble Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1805
31. T. Pawson Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems Cell 116 2004 191 203
32. S.H. Kang Non-phosphopeptide inhibitor for Lck SH2 domain: solid-phase synthesis and structure activity relationship of rosmarinic acid analogs Bull. Korean Chem. Soc. 24 2003 664 666
33. W.C. Shakespeare Structure-based design of novel bicyclic nonpeptide inhibitors for the src SH2 domain J. Med. Chem. 43 2000 3815 3819
34. S. Giorgetti-Peraldi Cellular effects of phosphotyrosine-binding domain inhibitors on insulin receptor signaling and trafficking Mol. Cell. Biol. 17 1997 1180 1188
35. B. Al-Lazikani Combining multiple structure and sequence alignments to improve sequence detection and alignment: application to the SH2 domains of Janus kinases Proc. Natl. Acad. Sci. U. S. A. 98 2001 14796 14801
36. M. Chen The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals Proc. Natl. Acad. Sci. U. S. A. 94 1997 6910 6915
37. J. Girault The N-termini of FAK and JAKs contain divergent band 4.1 domains Trends Biochem. Sci. 24 1999 54 57
38. K. Hamada Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain EMBO J. 19 2000 4449 4462
39. M. Pearson Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain Cell 101 2000 259 270
40. Y-J. Zhou Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases Mol. Cell 8 2001 959 969
41. P. Saharinen Regulation of the JAK2 tyrosine kinase domain by its pseudokinase domain Mol. Cell. Biol. 20 2000 3387 3395
42. R. Malaviya, and F.M. Uckun Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis J. Biol. Chem. 274 1999 27028 27038
43. J. Tian Infectious Th1 and Th2 autoimmunity in diabetes-prone mice Immunol. Rev. 164 1998 119 127
44. P. Macchi Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) Nature 377 1995 65 68
45. P.J. Tortolani Regulation of JAK3 expression and activation in human B cells and B cells malignancies J. Immunol. 155 1995 5220 5226
46. A.C. Ward The Jak-Stat pathway in normal and perturbed hematopoiesis Blood 95 2000 19 29
47. B.M. Hall Cells mediating allograft rejection Transplantation 51 1991 1141 1151
48. M.D. Saemann Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3 Am. J. Transplant. 3 2003 1341 1349